A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
Status:
Completed
Trial end date:
2015-06-04
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to investigate the safety, tolerability of the novel plasma
kallikrein inhibitor, KVD001 in subjects with diabetic macular edema. The study is the first
step to investigate the hypothesis that plasma kallikrein plays an important role in the
disease process behind diabetic macular edema in many patients